Manufacturer VerifiedFrance
Vetoquinol S.A.
Vetoquinol
Vetoquinol is a fiercely independent, family-influenced French animal health company that has steadfastly pursued an "Essential Products" focused strategy since its founding in 1933. Headquartered in Lure, Bourgogne-Franche-Comté, France, Vetoquinol generated EUR 525.7 million in 2025 revenue, employing 2,486 employees across 5 integrated production sites. Companion animals now represent 70% of total revenue, anchored by Vetoquinol's legendary 75.8% gross purchasing margin—one of the highest in the industry—achieved through the obsessive vertical integration of its flagship "LILAS" autonomous dry forms production complex in Lure, where all oral solid dosage products are manufactured end-to-end in a completely self-contained, highly automated environment.
Strengths:
• Extraordinary Manufacturing Efficiency: 75.8% gross purchasing margin—among the highest in the global animal health industry—driven by the LILAS complex's fully autonomous solid dosage production
• Companion Animal Purity: 70% of revenue from companion animals, with deep specialization in cardiology, nephrology (Ipakitine), and hepatology (Zentonil)
• Financial Independence: Debt-averse, family-influenced governance with zero reliance on leverage-fueled M&A, generating EUR 72 million in free cash flow in 2025
• Veterinarian Trust: Multi-decade relationships with European veterinary practitioners built on consistent product quality and clinical reliability
• Lean Operating Model: 5 focused production sites globally, each optimized for specific dosage forms, avoiding the complexity and overhead of sprawling multi-site networks
Weaknesses:
• Sub-Scale Revenue Base: At EUR 525.7M, Vetoquinol's absolute R&D budget is materially smaller than competitors, limiting investment in novel biologics and next-generation therapeutics
• Geographic Concentration: Heavy reliance on European markets (particularly France) creates vulnerability to regional economic downturns and regulatory changes
• Limited Innovation Pipeline: The "Essential Products" strategy, while profitable, has resulted in a conservative R&D pipeline with few disruptive innovations compared to larger competitorsRead MoreShow Less
Strengths:
• Extraordinary Manufacturing Efficiency: 75.8% gross purchasing margin—among the highest in the global animal health industry—driven by the LILAS complex's fully autonomous solid dosage production
• Companion Animal Purity: 70% of revenue from companion animals, with deep specialization in cardiology, nephrology (Ipakitine), and hepatology (Zentonil)
• Financial Independence: Debt-averse, family-influenced governance with zero reliance on leverage-fueled M&A, generating EUR 72 million in free cash flow in 2025
• Veterinarian Trust: Multi-decade relationships with European veterinary practitioners built on consistent product quality and clinical reliability
• Lean Operating Model: 5 focused production sites globally, each optimized for specific dosage forms, avoiding the complexity and overhead of sprawling multi-site networks
Weaknesses:
• Sub-Scale Revenue Base: At EUR 525.7M, Vetoquinol's absolute R&D budget is materially smaller than competitors, limiting investment in novel biologics and next-generation therapeutics
• Geographic Concentration: Heavy reliance on European markets (particularly France) creates vulnerability to regional economic downturns and regulatory changes
• Limited Innovation Pipeline: The "Essential Products" strategy, while profitable, has resulted in a conservative R&D pipeline with few disruptive innovations compared to larger competitors
FranceFounded 19332,486EUR$526 M5 integrated production sites… / 100
Listed onEURONEXTVETO
Listed market data
VETO · Euronext · weeklyHistory →- Market cap
- $1 B
- Share price
- ≈ EUR 87.95
- 1Y change
- -4.2%
- Recent change
- +1.9%
- Since first close
- +245.6%
- Revenue (TTM)
- $610 M
10-22 → 10-23
from 2006-11
Revenue FY 2025 · updated 2026-10-23Source ↗
Financial history
Full market historyMonthCloseMarket capChange
- 2026-10EUR 78.30$908 M0.0%
- 2026-09EUR 78.30$908 M+3.2%
- 2026-08EUR 75.90$880 M+9.5%
- 2026-07EUR 69.30$804 M-5.1%
- 2026-06EUR 73.00$847 M+3.0%
- 2026-05EUR 70.90$822 M-1.7%
- 2026-04EUR 72.10$836 M-6.4%
- 2026-03EUR 77.00$893 M-2.2%
- 2026-02EUR 78.70$913 M-7.1%
- 2026-01EUR 84.70$982 M-2.5%
- 2025-12EUR 86.90$1 B+4.1%
- 2025-11EUR 83.50$968 M—
Monthly closes · 2025-11 – 2026-10 · Full market history
In the press
All coverage →5 latest headlines1- Vetoquinol USA Recalls FOLLTROPIN Injectable Kits Due to Presence of Particulate Matter in Vials - Pet Agewww.petage.com2025-12-03
- Vetoquinol: 2026 Half Year Results - Yahoo Financefinance.yahoo.com2026-09-10
- Vetoquinol (CEUX:VETOP) Cyclically Adjusted Price-to-FCF : (As of Oct. 08, 2026) - GuruFocuswww.gurufocus.com2026-10-08
- Vetoquinol (CEUX:VETOP) Cyclically Adjusted PB Ratio : (As of Oct. 08, 2026) - GuruFocuswww.gurufocus.com2026-10-08
- Vetoquinol (CEUX:VETOP) Cyclically Adjusted PS Ratio : (As of Oct. 14, 2026) - GuruFocuswww.gurufocus.com2026-10-08
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.
Vetoquinol is a fiercely independent, family-influenced French animal health company founded in 1933, operating with a distinct "Essential Products" focused strategy. The company eschews the debt-fueled mega-M&A approach of its peers, instead concentrating all its resources on a carefully curated portfolio of core therapeutic products.
Its industrial crown jewel is the "LILAS" complex in Lure, France—a state-of-the-art autonomous dry forms production unit housing over 300 employees, where all oral solid dosage products including its market-leading hepatology, urology, and cardiovascular tablets are manufactured from raw material blending through compression, coating, and sealed packaging in a completely self-contained, highly automated environment. This obsessive control over solid dosage manufacturing yields an extraordinary 75.8% gross purchasing margin. In total, Vetoquinol operates 5 integrated production sites globally.
Its industrial crown jewel is the "LILAS" complex in Lure, France—a state-of-the-art autonomous dry forms production unit housing over 300 employees, where all oral solid dosage products including its market-leading hepatology, urology, and cardiovascular tablets are manufactured from raw material blending through compression, coating, and sealed packaging in a completely self-contained, highly automated environment. This obsessive control over solid dosage manufacturing yields an extraordinary 75.8% gross purchasing margin. In total, Vetoquinol operates 5 integrated production sites globally.
Companion Animal Core Products — Core Business
• Cardiology & Hypertension: cardiovascular therapeutics
• Nephrology & Urology: Ipakitine for chronic kidney disease
• Hepatology: Zentonil for liver support
• Anti-infectives: Marbofloxacin-based antibiotics
• Anti-inflammatories & Pain Management
• Nutritional Supplements
• Cardiology & Hypertension: cardiovascular therapeutics
• Nephrology & Urology: Ipakitine for chronic kidney disease
• Hepatology: Zentonil for liver support
• Anti-infectives: Marbofloxacin-based antibiotics
• Anti-inflammatories & Pain Management
• Nutritional Supplements
Quick Facts
Headquarters
Lure, Bourgogne-Franche-Comté, France
Founded
1933
Employees
2,486
Revenue
EUR$526 M (2025)
Market cap
$1 B
Factories
5 integrated production sites globally
Presence
Products sold in 100+ countries, direct operations in 24 countries
Listing
Euronext Paris: VETO
Categories
10 categories · scroll for more
Related
Similar listed companies
- Nvidia Corporation· $5.2 T
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website Euronext Paris: VETO , Vetoquinol Official Website
Euronext — Vetoquinol (VETO)
Wikipedia — Vetoquinol